Literature DB >> 12220217

DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck.

Erich M Sturgis1, Kristina R Dahlstrom, Margaret R Spitz, Qingyi Wei.   

Abstract

OBJECTIVE: To determine the effect of the ERCC1 C8092A polymorphism and the ERCC2/XPD G23591A polymorphism on the risk of squamous cell carcinoma of the head and neck (SCCHN).
DESIGN: A hospital-based case-control study.
SUBJECTS: A total of 330 newly diagnosed case subjects with SCCHN and 330 cancer-free control subjects matched on age (+/- 5 years), sex, smoking status, and alcohol use. All subjects were non-Hispanic whites.
METHODS: After informed consent was obtained, blood was drawn for genotyping. The ERCC1 C8092A polymorphism was typed by single-strand conformational polymorphism analysis. The ERCC2/XPD G23591A polymorphism was typed by polymerase chain reaction-based restriction fragment length polymorphism analysis with the enzyme StyI. The chi(2) analysis was used to assess differences in genotype and allele frequencies. Multivariate logistic regression analysis was performed to estimate the risk of SCCHN for individuals having these genotypes after adjustment for age, sex, tobacco smoking, and alcohol use.
RESULTS: The DNA was available and genotyping was ultimately successful for 313 case subjects and 313 control subjects. The ERCC1 8092CC genotype and the ERCC2/XPD 23591A allele were associated with nonsignificantly increased risks of SCCHN: odds ratios, 1.15 (95% confidence interval [CI], 0.84-1.59) and 1.28 (95% CI, 0.93-1.76), respectively, whereas having both risk genotypes was associated with an even higher risk of SCCHN: odds ratio, 1.78 (95% CI, 0.99-3.17). When considering both polymorphisms, we found a significant allele dose effect (P =.04).
CONCLUSIONS: These 2 polymorphisms may contribute to the risk of SCCHN, but larger studies are needed to confirm their role in SCCHN. Combining common DNA repair gene polymorphisms into models of genetic risk of SCCHN may improve risk estimates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220217     DOI: 10.1001/archotol.128.9.1084

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  26 in total

1.  Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients.

Authors:  So-Yeon Park; Yun-Chul Hong; Jin-Hee Kim; Seung-Min Kwak; Jae-Hwa Cho; Hong-Lyeol Lee; Jeong-Seon Ryu
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis.

Authors:  Jing Cui; Dalu Li; Liang Shen; Wenmei Zhang; Xin Xu
Journal:  Tumour Biol       Date:  2014-03-22

3.  Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.

Authors:  Y W Ding; X Gao; D X Ye; W Liu; L Wu; H Y Sun
Journal:  Clin Transl Oncol       Date:  2015-05-29       Impact factor: 3.405

4.  ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma.

Authors:  Hitoshi Hirakawa; Taro Ikegami; Satoe Azechi; Shinya Agena; Jin Uezato; Hidetoshi Kinjyo; Yukashi Yamashita; Katsunori Tanaka; Shunsuke Kondo; Hiroyuki Maeda; Mikio Suzuki; Akira Gahana
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-11-20       Impact factor: 2.503

Review 5.  Polymorphisms in DNA damage response genes and head and neck cancer risk.

Authors:  Rafael E Flores-Obando; Susanne M Gollin; Camille C Ragin
Journal:  Biomarkers       Date:  2010-08       Impact factor: 2.658

Review 6.  Polymorphisms in human DNA repair genes and head and neck squamous cell carcinoma.

Authors:  Rim Khlifi; Ahmed Rebai; Amel Hamza-Chaffai
Journal:  J Genet       Date:  2012       Impact factor: 1.166

7.  Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population.

Authors:  Nathan R Jones; Thomas E Spratt; Arthur S Berg; Joshua E Muscat; Philip Lazarus; Carla J Gallagher
Journal:  Cancer Epidemiol       Date:  2010-09-21       Impact factor: 2.984

8.  Genetic variation in multiple biologic pathways, flavonoid intake, and breast cancer.

Authors:  Nikhil K Khankari; Patrick T Bradshaw; Lauren E McCullough; Susan L Teitelbaum; Susan E Steck; Brian N Fink; Xinran Xu; Jiyoung Ahn; Christine B Ambrosone; Katherine D Crew; Mary Beth Terry; Alfred I Neugut; Jia Chen; Regina M Santella; Marilie D Gammon
Journal:  Cancer Causes Control       Date:  2013-11-27       Impact factor: 2.506

9.  Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation.

Authors:  L Mannarini; G Bertino; P Morbini; C Villa; M Benazzo
Journal:  Acta Otorhinolaryngol Ital       Date:  2007-08       Impact factor: 2.124

10.  XPD Polymorphisms and Risk of Squamous Cell Carcinoma of the Head and Neck in a Korean Sample.

Authors:  Yong Bae Ji; Kyung Tae; Yoon Seo Lee; Seung Hwan Lee; Kyung Rae Kim; Chul Won Park; Byung Lae Park; Hyoung Doo Shin
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.